---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-005225"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T20:58:30.737973+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Aptose Q2 net loss $14.1M; TUS/VEN doublet 50% CRc; Hanmi commits up to $7M

## Summary
- TUS/VEN doublet: 50% CRc (5/10 evaluable); 44% CRc in prior-venetoclax failures (4/9); 43% in FLT3-WT (3/7).
- Hanmi Pharma commits up to $7M or 19.99% ownership in two tranches; first $3M by Aug-end conditional on TSX listing.
- Q2 net loss $14.1M vs $10.6M prior year; cash $23.3M at June 30, expected to fund operations through March 2024.
- FDA End of Phase 1 meeting completed; monotherapy RP2D of 80 mg daily confirmed; accelerated path remains open.

## SEC filing metadata
- accession: 0001171843-23-005225
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184323005225/0001171843-23-005225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184323005225/f8k_081023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-005225
- JSON: https://secwatch.observer/filing/0001171843-23-005225.json
- Plain text: https://secwatch.observer/filing/0001171843-23-005225.txt

## Key facts
- Earnings Releases
  Aptose Biosciences Inc. reported three months ended June 30, 2023 results: net income $(14,129 ) thousand, EPS $(2.27 ) per share.
  - Period: three months ended June 30, 2023
  - Net income: $(14,129 ) thousand
  - EPS: $(2.27 ) per share
  - Result: reported results
  source text: Aptose Reports Results for the Second Quarter 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000117184323005225/0001171843-23-005225-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.